Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "CDMO"

325 News Found

Akums reports Q1 FY26 PAT at Rs. 65 Cr
News | August 09, 2025

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals


Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
News | August 08, 2025

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025


Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers
News | August 03, 2025

Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers

The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product


iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025
News | August 01, 2025

iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025

A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide


Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
News | August 01, 2025

Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr

Our specialty chemical businesses have continued to perform strongly, growing double digit YoY


Aurobindo to acquire Lannett Company for Rs. 2,185 Cr
News | July 31, 2025

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities


Astec LifeSciences Q1 FY26 revenue up 30.3%
News | July 29, 2025

Astec LifeSciences Q1 FY26 revenue up 30.3%

The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year


Lonza reports 19% growth in sales in H1
News | July 23, 2025

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook